Could infants with fast heartbeat stop meds sooner?
NCT ID NCT04837261
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looked at whether infants with supraventricular tachycardia (SVT) can safely stop antiarrhythmic medication after just 4 months instead of longer. Researchers followed 107 infants aged 6 months or younger who were treated with drugs like propranolol or flecainide. The main goal was to see how many had a return of SVT after stopping medication early.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Propranolol, Flecainide, Amiodarone
What this could lead to
If successful, this could show that a shorter course of medication is safe and effective for infants with SVT, reducing drug exposure.
What could go wrong
This is an observational study, not a randomized trial, so results may be less reliable. The shorter course might lead to more recurrences of SVT.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SUPRAVENTRICULAR TACHYCARDIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Central Finland Central Hospital
Jyväskylä, Central Finland, 40620, Finland
-
Helsinki University Hospital
Helsinki, Uusimaa, 00029, Finland
-
Hämeenlinna Central Hospital
Hämeenlinna, Kanta-Häme, 13530, Finland
-
Kajaani Central Hospital
Kajaani, Kainuu, 87300, Finland
-
Kokkola Central Hopsital
Kokkola, Keski-Pohjanmaa, 67200, Finland
-
Kuopio University Hospital
Kuopio, Northern Savonia, 70029, Finland
-
Kymenlaakso Central Hospital
Kotka, Region of Kymenlaakso, 48210, Finland
-
Lahti Central Hospital
Lahti, Paijat-Hame Region, 15850, Finland
-
Lapland Central Hospital
Rovaniemi, Lapland, 96101, Finland
-
Mikkeli Central Hospital
Mikkeli, South Savo, 50100, Finland
-
North Karelia Central Hospital
Joensuu, Pohjois-Karjala, 80210, Finland
-
Oulu University Hospital
Oulu, North Ostrobothnia, 90220, Finland
-
Sakunta Central Hospital
Pori, Satakunta, 28500, Finland
-
Seinäjoki Central Hospital
Seinäjoki, South Ostrobothnia, 60220, Finland
-
South Karelia Central Hospital
Lappeenranta, South Karelia Region, 53130, Finland
-
Tampere University Hospital
Tampere, Pirkanmaa, 33520, Finland
-
Turku University Hospital
Turku, Southwest, 20521, Finland
-
Vaasa Central Hospital
Vaasa, Pohjanmaa, 65130, Finland